Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in severe eosinophilic asthma (MENSA)
NCT01691521Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2012
- Primary completion
- Jan 2014
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of mepolizumab in eosinophilic asthma (EA) (3 arms), sponsored by GSK. Primary endpoint: Number of Clinically Significant Exacerbations of Asthma Per Year at 32 weeks. Started Oct 2012; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT01691521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01691521.